Treg Cell And PD-1 In Cancer Immunotherapy

Author:

Feng Haomin,Wang Jiayue,Yu Ruibo

Abstract

Cancer results from the abnormal life activity of some cells in the human body. These abnormal life activities are mainly reflected in uncontrolled division and proliferation and can infiltrate and destroy normal human tissues. In actuality, more than a million people die from cancer annually, and it ranks first among the main causes of death globally. Common cancers include skin cancer, lung cancer, gastric cancer, pancreatic cancer, etc. In the modern era, immunotherapy is the mainstay of treatment for some relatively common cancers, such as breast and prostate cancer. There are many ways to treat cancer in the world. In this article, the author only compares two possible ways to treat cancer: Treg cell method and PD-1 therapy. This paper tried to clarify the advantages and disadvantages of these two immunotherapies in cancer treatment by studying and comparing the two immunotherapies for cancer treatment, to help researchers find better ways to treat cancer with immunotherapy.

Publisher

Darcy & Roy Press Co. Ltd.

Reference11 articles.

1. Cancer statistics based on combined data from England, Scotland, Northern Ireland and Wales. World Cancer Research Fund, 2022. https://www.wcrf-uk.org/preventing-cancer/uk-cancer-statistics/.

2. Foldvari M, Chen DW, Nafissi N, et al. non-viral gene therapy: gains and challenges of non-invasive administration methods. J Control Release. 2016; 240:165-190.

3. Gholami A, Roshanfard F, Ghasemi Y. A comprehensive review of gene therapy, recent progress and future prospects. Razi J Med Sci. 2016;23(149):28-45.

4. Foss FM.DAB (389) IL-2 (ONTAK): a novel fusion toxin therapy for lymohoma [J]. Clini Lymohoma. 2000,1(2):110-116.

5. Goubran, Hadi A. et al. “Regulation of Tumor Growth and Metastasis: The Role of Tumor Microenvironment.” Cancer Growth and Metastasis 2014.2014 (2014): 9–18.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3